Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Exosomes and Circulating Biomarkers Summit 2013

Mostafa Ronaghi's Biography



Mostafa Ronaghi, Senior Vice President And Chief Technology Officer, Illumina Inc

Mostafa Ronaghi, Ph.D., joined Illumina in August 2008. As Senior Vice President and Chief Technology Officer, he is responsible for leading internal research and the Illumina accelerator program. Dr. Ronaghi is an experienced entrepreneur and was involved in the start-up of four life sciences companies. In 2007, Ronaghi co-founded Avantome, a privately held sequencing company (acquired by Illumina in 2008). Before this, he co-founded NextBio, a search engine for life science data (acquired by Illumina in 2013). In 2001, Ronaghi co-founded ParAllele Bioscience, which was eventually acquired by Affymetrix, Inc., and was involved in the development and commercialization of highly multiplexed technology for genetic testing. In 1997, he co-founded Pyrosequencing AB, which was renamed to Biotage in 2003, and led the company to a successful initial public offering in June 2000 on the Stockholm Stock Exchange. Dr. Ronaghi was a principal investigator at Stanford University from 2002­ until 2008 and focused on the development of novel tools for molecular diagnostic applications. He serves on the board of directors of Clear Labs and BaseHealth. Dr. Ronaghi earned his Ph.D. from the Royal Institute of Technology in Sweden. He holds more than 30 (pending and issued) patents and has written more than 70 peer-reviewed publications in journals and books.

Mostafa Ronaghi Image

Use of Nextgen to Study Circulating Biomarkers

Friday, 13 September 2013 at 11:15

Add to Calendar ▼2013-09-13 11:15:002013-09-13 12:15:00Europe/LondonUse of Nextgen to Study Circulating BiomarkersExosomes and Circulating Biomarkers Summit 2013 in San Diego, CASan Diego, CASELECTBIOenquiries@selectbiosciences.com

A paradigm shift has happened with drastic cost reduction and improvements in the workflow and accuracy of Nextgen sequencing. In general, Nextgen is replacing several classical clinical tests by improved accuracy, enhanced safety for patient, and lower cost of test. In this talk, recent progress in Nextgen sequencing will be discussed. Furthermore, several examples will be provided on how Nextgen is being implemented to study circulating biomarkers in biological fluids.


Add to Calendar ▼2013-09-12 00:00:002013-09-13 00:00:00Europe/LondonExosomes and Circulating Biomarkers Summit 2013Exosomes and Circulating Biomarkers Summit 2013 in San Diego, CASan Diego, CASELECTBIOenquiries@selectbiosciences.com